Inventor · disambiguated record
Paul Hollenbach
Also filed as: HOLLENBACH PAUL
3 granted patents·5 pending applications·13 citations·filing 2008–2023
65Inventor score
Top patents by PatentIndex Score
8 records- 0189US10996215B2Methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancersCELGENE CORP·Filed 2018·Granted May 4, 2021·5 cites·21 claims
- 0288US10245258B2Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideCELGENE CORP·Filed 2017·Granted Apr 2, 2019·8 cites·43 claims
- 0376US2023158009A1Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideCELGENE CORP·Filed 2023·Application pending·0 cites
- 0468US11590117B2Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideCELGENE CORP·Filed 2020·Granted Feb 28, 2023·0 cites·21 claims
- 0567US2022003749A1Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancersCELGENE CORP·Filed 2021·Application pending·0 cites
- 0659US2019175573A1Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideCELGENE CORP·Filed 2019·Application pending·0 cites
- 0754US2016313300A1Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancersCELGENE CORP·Filed 2014·Application pending·0 cites
- 0844US2010086518A1Treatment of melanomaNOVARTIS AG·Filed 2008·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Paul Hollenbach files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →